# NextCell Starts a Phase-I Study of Mesenchymal Stromal Cell Treatment

**URL:** <https://forum.fudiabetes.org/t/nextcell-starts-a-phase-i-study-of-mesenchymal-stromal-cell-treatment/5019>\
**Category:** T1 Research\
**Created:** [September 18, 2018, 3:58am UTC](https://forum.fudiabetes.org/t/nextcell-starts-a-phase-i-study-of-mesenchymal-stromal-cell-treatment/5019 "2018-09-18T03:58:37Z")\
**Posts on this page:** 2\
**Page:** 1

<div class="post-metadata">

**Author:** ![joshualevy](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.fudiabetes.org/joshualevy/32/2189_2.png) [@joshualevy](https://forum.fudiabetes.org/u/joshualevy)\
**Post date:** [September 18, 2018, 3:58am UTC](https://forum.fudiabetes.org/t/nextcell-starts-a-phase-i-study-of-mesenchymal-stromal-cell-treatment/5019/1 "2018-09-18T03:58:37Z")

</div>

I’ve written a blog on a study using a specific type of umbilical cord stem cell to try to cure type-1 diabetes in honeymooners:

> **[NextCell Starts a Phase-I Study of Mesenchymal Stromal Cell Treatment](https://cureresearch4type1diabetes.blogspot.com/2018/09/nextcell-starts-phase-i-study-of.html)**
>
> NextCell pharma is running a clinical trial of their ProTrans product.  This is a stem cell product derived from "Wharton´s Jelly", which is...

The good news, is that the study is already running, and should have some very early results in October.

Joshua Levy

---

<div class="post-metadata">

**Author:** ![Michel](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.fudiabetes.org/michel/32/387_2.png) [@Michel](https://forum.fudiabetes.org/u/Michel)\
**Post date:** [September 18, 2018, 8:28am UTC](https://forum.fudiabetes.org/t/nextcell-starts-a-phase-i-study-of-mesenchymal-stromal-cell-treatment/5019/2 "2018-09-18T08:28:44Z")

</div>

@joshualevy, this is fascinating!

I found the doc slightly difficult to read on a cellphone, so I am adding a little more info below:

- Purpose of the study is to evaluate if it is possible to prolong or increase self-production of (= endogenous) insulin by T1D patients.
- To that purpose, study tests possible subjects with c-peptide test, to verify they still produce some insulin
- The cells they inject, although hexogenous (from another donor), have a low likelihood to be rejected, so they don’t need to use immuno-suppressants (anti-reject meds).
- The risk of rejection is the reason why they don’t use women in stage 1.

It is a fairly fast study! Full results should be available in less than 2 years.

@joshualevy, feel free to correct as needed 🙂